Alzinova AB
78D
Company Profile
Business description
Alzinova AB is a Swedish biotechnology company engaged in the discovery and development of therapeutics for the treatment of Alzheimer's disease. The company is developing ALZ-101, an oligomer-specific therapeutic vaccine currently advancing toward Phase 2 clinical development, and ALZ-201, a monoclonal antibody targeting toxic amyloid-beta (AB) oligomers, which is in preclinical development. The company's proprietary ABCC peptide technology is focused on disease-modifying treatments for Alzheimer's disease.
Contact
Entreprenorsstraket 10
GoCo House
Molndal431 53
SWESector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
7
Stocks News & Analysis
stocks
AI stocks stumble amid growing safety fears
Warnings from Anthropic, OpenAI, and SpaceX are raising questions over the future of the AI buildout.
stocks
Chart of the Week: BHP’s valuation hits historic levels
BHP and peers are trading as if the copper boom is here to stay.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,910.90 | 36.40 | 0.41% |
| CAC 40 | 8,186.93 | 0.00 | 0.00% |
| DAX 40 | 25,716.71 | 178.96 | 0.70% |
| Dow JONES (US) | 51,778.04 | 316.14 | 0.61% |
| FTSE 100 | 10,816.14 | 127.67 | 1.19% |
| HKSE | 24,604.29 | 109.49 | -0.44% |
| NASDAQ | 26,418.30 | 439.87 | 1.69% |
| Nikkei 225 | 64,136.25 | 213.25 | 0.33% |
| NZX 50 Index | 13,756.59 | 133.87 | 0.98% |
| S&P 500 | 7,637.76 | 85.95 | 1.14% |
| S&P/ASX 200 | 8,732.40 | 35.90 | 0.41% |
| SSE Composite Index | 3,875.60 | 16.00 | -0.41% |